Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Nutr Res. 2018 Jun;54:40-51. doi: 10.1016/j.nutres.2018.03.015. Epub 2018 Apr 6.
Chronic low-grade inflammation is the hallmark of type 2 diabetes (T2D). Although in vitro and animal studies have shown that resveratrol exerts anti-inflammatory effects, clinical trials addressing these effects in patients with T2D are limited. Therefore, in the present study, we hypothesized that supplementation of resveratrol might improve inflammatory markers in patients with T2D in a randomized, double-blind, placebo-controlled clinical trial. A total of 45 T2D patients were supplemented with either of 800 mg/d resveratrol or placebo capsules for 8 weeks. Percentage of CD14CD16 monocytes, plasma levels of inflammatory cytokines (tumor necrosis factor α, interleukin [IL] 1β, IL-6, and monocyte chemoattractant protein-1), the expression levels of genes involved in the inflammatory responses (toll-like receptor 2, toll-like receptor 4, and nuclear factor κB), lipopolysaccharide-stimulated cytokine (tumor necrosis factor α, IL-1β, and IL-6) secretion from peripheral blood mononuclear cells, and metabolic and anthropometric parameters were assessed at both the baseline level and the end of the study. Compared with the placebo group, we could not detect any significant difference in the percentage of CD14CD16 monocytes, lipopolysaccharide-induced cytokine secretion, plasma levels of inflammatory cytokines, and the expression of inflammatory genes in resveratrol group. Moreover, we did not find any significant change in the metabolic and anthropometric parameters except for a significant reduction in fasting blood glucose and blood pressure. In conclusion, 8-week supplementation of resveratrol reduces blood glucose level in patients with T2D without improving their inflammatory markers.
慢性低度炎症是 2 型糖尿病（T2D）的标志。虽然体外和动物研究表明白藜芦醇具有抗炎作用，但针对 T2D 患者这些作用的临床试验是有限的。因此，在本研究中，我们假设在一项随机、双盲、安慰剂对照的临床试验中，白藜芦醇补充可能会改善 T2D 患者的炎症标志物。共有 45 名 T2D 患者接受 800mg/d 白藜芦醇或安慰剂胶囊补充 8 周。用流式细胞术检测 CD14CD16 单核细胞的百分比，用酶联免疫吸附试验检测炎症细胞因子（肿瘤坏死因子-α、白细胞介素[IL]-1β、IL-6 和单核细胞趋化蛋白-1）的血浆水平，用实时聚合酶链反应检测参与炎症反应的基因（Toll 样受体 2、Toll 样受体 4 和核因子κB）的表达水平，用脂多糖刺激外周血单核细胞后检测细胞因子（肿瘤坏死因子-α、IL-1β 和 IL-6）的分泌，并在基线水平和研究结束时评估代谢和人体测量参数。与安慰剂组相比，我们在白藜芦醇组中未检测到 CD14CD16 单核细胞的百分比、脂多糖诱导的细胞因子分泌、炎症细胞因子的血浆水平和炎症基因的表达有任何显著差异。此外，除了空腹血糖和血压有显著降低外，我们没有发现任何代谢和人体测量参数的显著变化。总之，8 周白藜芦醇补充可降低 T2D 患者的血糖水平，但不能改善其炎症标志物。
